Steven Wise, MD
Allergy & Immunology · Indianapolis, INNPI 1740262211
Payments from drug & device makers
Across 786 payments — averaging $173.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$93K
- Teva Pharmaceuticals USA, Inc.$8K
- AstraZeneca$7K
- Genentech USA, Inc.$5K
- ARS Pharmaceuticals Operations, Inc.$4K
- Regeneron Healthcare Solutions, Inc.$4K
- plus $15K from 33 others
What the payments were for
- Consulting fees$9,9417%
- Speaking & faculty fees$97,80472%
- Travel & lodging$7,9926%
- Food & beverage$20,70315%
- Education$2630%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 224 | $93,203 |
| Teva Pharmaceuticals USA, Inc. | 36 | $8,016 |
| AstraZeneca | 92 | $7,357 |
| Genentech USA, Inc. | 20 | $5,483 |
| ARS Pharmaceuticals Operations, Inc. | 11 | $4,083 |
| Regeneron Healthcare Solutions, Inc. | 18 | $3,713 |
| Blueprint Medicines Corporation | 14 | $2,996 |
| Sanofi | 71 | $2,093 |
| Boehringer Ingelheim | 4 | $1,890 |
| Novartis | 60 | $1,855 |
| CSL Behring | 32 | $681 |
| Takeda Pharmaceuticals U.S.A., Inc. | 28 | $677 |
| Grifols USA, LLC | 19 | $586 |
| Amgen | 20 | $501 |
| Optinose US, Inc. | 20 | $442 |
| Genentech, Inc. | 3 | $400 |
| Kaleo, Inc. | 22 | $368 |
| Pfizer | 16 | $301 |
| Sanofi-aventis U.S. LLC | 5 | $235 |
| Octapharma USA, Inc. | 6 | $231 |
| Abbott | 16 | $208 |
| Pharming Healthcare, Inc. | 5 | $170 |
| Galderma Laboratories, L.p. | 6 | $167 |
| Covis Pharma GmbH | 7 | $165 |
| Shire North American Group Inc | 3 | $133 |
| AbbVie | 3 | $118 |
| Mylan Specialty L.p. | 1 | $113 |
| Ionis Pharmaceuticals, Inc. | 3 | $90 |
| Hospira, Inc. | 4 | $78 |
| Bio Products Laboratory USA, Inc. | 2 | $65 |
| Biocryst US Sales Co., LLC | 3 | $59 |
| Merck | 3 | $48 |
| Incyte Corporation | 1 | $39 |
| LEO Pharma Inc. | 2 | $36 |
| Hikma Pharmaceuticals USA | 2 | $33 |
| Sunovion Pharmaceuticals Inc. | 1 | $24 |
| ADMA Biomanufacturing LLC | 1 | $19 |
| Alk-abello, Inc | 1 | $13 |
| Biocryst Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AREXVY$45,432
- TRELEGY ELLIPTA$31,134
- ProAir Digihaler$7,525
- AirDuo RespiClick$7,525
- ArmonAir Digihaler$7,525
- XOLAIR$5,667
- DUPIXENT$3,919
- NEFFY$3,600
- FASENRA$2,298
- TEZSPIRE$737
- NUCALA$729
- AIRSUPRA$728
- AYVAKIT$254
- BREZTRI$241
- Xembify$166
- BEVESPI AEROSPHERE$122
- CUTAQUIG$121
- Xhance$119
- ALVESCO$113
- Yupelri$113
How this compares
$136,703 in reported general payments places this provider in the 85th percentile of 49 allergy & immunology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CuvitruImmun Glob G(Igg)/Gly/Iga Ov50 | 37 | $188,934 |
| HyqviaIgg/Hyaluronidase,recombinant | 13 | $185,589 |
| XolairOmalizumab | 50 | $149,813 |
| NucalaMepolizumab | 15 | $134,225 |
| FasenraBenralizumab | 14 | $80,358 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 97 | $77,325 |
| Breo ElliptaFluticasone/Vilanterol | 102 | $53,826 |
| Spiriva RespimatTiotropium Bromide | 38 | $33,609 |
| Qvar RedihalerBeclomethasone Dipropionate | 35 | $12,616 |
| Arnuity ElliptaFluticasone Furoate | 39 | $12,201 |
| Epinephrine | 50 | $11,559 |
| DuleraMometasone/Formoterol | 28 | $11,520 |
| SymbicortBudesonide/Formoterol Fumarate | 38 | $10,874 |
| Fluticasone Propionate HfaFluticasone Propionate | 33 | $8,504 |
| Advair HfaFluticasone Propion/Salmeterol | 14 | $7,934 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Cuvitru, Hyqvia | $677 | $374,52350 claims |
| GSKNucala, Trelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $93,203 | $277,576253 claims |
| Genentech, Inc.Xolair | $400 | $149,81350 claims |
| AstraZenecaFasenra, Symbicort, Pulmicort Flexhaler | $7,357 | $95,47967 claims |
| Boehringer IngelheimSpiriva Respimat | $1,890 | $33,60938 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $8,016 | $12,61635 claims |
| Hikma Pharmaceuticals USAEpinephrine | $33 | $11,55950 claims |
| MerckDulera | $48 | $11,52028 claims |
| Covis Pharma GmbHAlvesco | $165 | $6,49015 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 49 allergy & immunology providers in Indiana.
Other allergy & immunology in Indianapolis
- Pinkus GoldbergIndianapolis$89K
- Tolly EpsteinIndianapolis$8K
- Leanna Marie GershuniIndianapolis$6K
- Craig SewellIndianapolis$4K
- Douglas HortonIndianapolis$4K
- Maria Luisa Pilar ErmitanoIndianapolis$4K
- Jillian BelmonteIndianapolis$1K
- Dana AlhaffarIndianapolis$179
- James HarrisSouth Bend$1.7M
- Nabeel FarooquiFishers$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.